<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Degradation inducer</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>A first-in-class PRMT1-targeting PROTAC degrader</title>
      <description>
        <![CDATA[Protein arginine methyltransferase 1 (PRMT1) is a key enzyme that catalyzes post-translational arginine methylation, thereby regulating diverse cellular processes, including gene transcription, RNA splicing, signal transduction, and DNA damage repair. As a central epigenetic and signaling regulator, PRMT1 plays a critical role in coordinating cellular proliferation, differentiation, and survival.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730098</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730098-a-first-in-class-prmt1-targeting-protac-degrader</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Science-research-microscope.webp?t=1683923812" type="image/jpeg" medium="image" fileSize="168056">
        <media:title type="plain">Microscope with slide</media:title>
      </media:content>
    </item>
    <item>
      <title>Shanghai Meiyue Biotech Development patents new VAV1 degradation inducers</title>
      <description>
        <![CDATA[Shanghai Meiyue Biotech Development Co. Ltd. has disclosed new molecular glue degraders comprising an E3 ubiquitin-protein ligase binding agents coupled to proto-oncogene Vav (VAV1) acting as VAV1 degradation inducers reported to be useful for the treatment of cancer, autoimmune diseases, cardiovascular, renal, metabolic, inflammatory and neurological disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730069</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730069-shanghai-meiyue-biotech-development-patents-new-vav1-degradation-inducers</link>
    </item>
    <item>
      <title>Potential first-in-class RNF4 PROTAC for HCC disclosed</title>
      <description>
        <![CDATA[Ring finger protein 4 (RNF4) is a SUMO-targeted ubiquitin ligase that modulates proteins involved in cancer progression. Researchers from Chongqing Medical University and collaborators reported the development and preclinical characterization of [I], the first RNF4-targeting PROTAC degrader for the treatment of hepatocellular carcinoma (HCC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730063</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730063-potential-first-in-class-rnf4-protac-for-hcc-disclosed</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/cancer-liver-tumor-treatment.webp?t=1745257562" type="image/jpeg" medium="image" fileSize="179647">
        <media:title type="plain">Liver tumor treatment conceptual illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>HPK1 degradation inducers described in Biofront patent</title>
      <description>
        <![CDATA[Biofront Ltd. has designed new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety as HPK1 degradation inducers. They are described as potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730049</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730049-hpk1-degradation-inducers-described-in-biofront-patent</link>
    </item>
    <item>
      <title>BRD9 PROTAC shows efficacy in sarcoma and leukemia models</title>
      <description>
        <![CDATA[In both acute myeloid leukemia (AML) and synovial sarcoma (SS), targeting BRD9 disrupts oncogenic transcriptional programs, including MYC, leading to reduced proliferation and induction of apoptosis. Researchers from Pamplona Therapeutics (Shenzhen) Co. Ltd. reported the discovery and preclinical efficacy profile of XYD-270, a BRD9-targeting PROTAC, in models of SS and AML.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730016</guid>
      <pubDate>Mon, 30 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730016-brd9-protac-shows-efficacy-in-sarcoma-and-leukemia-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/leukemia-lymphoma-blood-cancer.webp?t=1724424490" type="image/jpeg" medium="image" fileSize="506006">
        <media:title type="plain">Art concept for hematologic cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS-986482 induces pan-IKZF degradation and robust tumor growth inhibition</title>
      <description>
        <![CDATA[IKZF1-4 are transcription factors that regulate cellular differentiation, proliferation and survival. At the American Chemical Society (ACS) Spring 2026 meeting this week in Atlanta, Bristol Myers Squibb Co. detailed the identification and preclinical profile of BMS-986482, a next-generation investigational cereblon E3 ligase modulator (CELMoD) degrader designed to target IKZF1-4 factors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729997</guid>
      <pubDate>Fri, 27 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729997-bms-986482-induces-pan-ikzf-degradation-and-robust-tumor-growth-inhibition</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Green-molecules.webp?t=1763673659" type="image/jpeg" medium="image" fileSize="568196">
        <media:title type="plain">Green molecules</media:title>
      </media:content>
    </item>
    <item>
      <title>Arvinas patents new PROTACs for the degradation of BCL-6</title>
      <description>
        <![CDATA[Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTACs) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a B-cell lymphoma 6 protein (BCL-6)-targeting moiety through a linker with potential for use in the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729887</guid>
      <pubDate>Wed, 25 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729887-arvinas-patents-new-protacs-for-the-degradation-of-bcl-6</link>
    </item>
    <item>
      <title>Qilu Pharma describes new VAV1 degradation inducers</title>
      <description>
        <![CDATA[Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has prepared and tested molecular glue degraders comprising E3 ubiquitin-protein ligases acting as proto-oncogene Vav (VAV1) degradation inducers reported to be useful for the treatment of inflammation and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729869</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729869-qilu-pharma-describes-new-vav1-degradation-inducers</link>
    </item>
    <item>
      <title>Daiichi Sankyo patents SF-1 degradation inducers</title>
      <description>
        <![CDATA[Daiichi Sankyo Co. Ltd. has disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a steroidogenic factor 1 (SF-1)-targeting moiety. They are reported to be potentially useful for the treatment of primary aldosteronism, Cushing syndrome and cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729803</guid>
      <pubDate>Mon, 23 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729803-daiichi-sankyo-patents-sf-1-degradation-inducers</link>
    </item>
    <item>
      <title>New Danish research program targets α-synuclein in Parkinson’s</title>
      <description>
        <![CDATA[A new Danish research project focused on Parkinson’s disease has received funding from Innovation Fund Denmark. The DESYNA (Degradation of Extracellular α-SYNuclein Aggregates) project aims to develop a new therapy targeting α-synuclein, the accumulation of which is a key driver of Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729792</guid>
      <pubDate>Mon, 23 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729792-new-danish-research-program-targets-synuclein-in-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Alpha-synuclein.webp?t=1719584612" type="image/jpeg" medium="image" fileSize="77677">
        <media:title type="plain">3D structure model of α-synuclein</media:title>
      </media:content>
    </item>
    <item>
      <title>Treeline Biosciences reports TEAD degraders</title>
      <description>
        <![CDATA[Treeline Biosciences Inc. has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to transcriptional enhancer factor TEF (TEAD)-targeting moiety potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729784</guid>
      <pubDate>Fri, 20 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729784-treeline-biosciences-reports-tead-degraders</link>
    </item>
    <item>
      <title>Innocare presents new VAV1 degradation inducers</title>
      <description>
        <![CDATA[Beijing Innocare Pharma Tech Co. Ltd. and Innocare Pharma Inc. have patented molecular glue degraders acting as VAV1 degradation inducers. They are reported to be useful for the treatment of autoimmune disease and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729733</guid>
      <pubDate>Thu, 19 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729733-innocare-presents-new-vav1-degradation-inducers</link>
    </item>
    <item>
      <title>University of Texas patents new YAP1 PROTACs</title>
      <description>
        <![CDATA[A University of Texas System patent describes new YAP1 degradation inducing proteolysis targeting chimeras (PROTACs) designed for use in the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729684</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729684-university-of-texas-patents-new-yap1-protacs</link>
    </item>
    <item>
      <title>VAV1 degradation inducers reported in new Humanwell Healthcare patents</title>
      <description>
        <![CDATA[Humanwell Healthcare (Group) Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN)-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are reported to be useful for the treatment of autoimmune disease, cancer, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, periodontitis, psoriasis, rheumatoid arthritis and type I diabetes, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729603</guid>
      <pubDate>Wed, 11 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729603-vav1-degradation-inducers-reported-in-new-humanwell-healthcare-patents</link>
    </item>
    <item>
      <title>Gilead Sciences discovers KRAS G12D mutant inhibitors</title>
      <description>
        <![CDATA[A patent from Gilead Sciences Inc. has divulged GTPase KRAS (G12D mutant) inhibitors and proteolysis targeting chimeras (PROTACS) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety through linker.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729401</guid>
      <pubDate>Fri, 06 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729401-gilead-sciences-discovers-kras-g12d-mutant-inhibitors</link>
    </item>
    <item>
      <title>Risen Pharma synthesizes PROTAC KRAS degraders</title>
      <description>
        <![CDATA[A Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. patent describes the discovery of new proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS-targeting moiety. They are reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729382</guid>
      <pubDate>Thu, 05 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729382-risen-pharma-synthesizes-protac-kras-degraders</link>
    </item>
    <item>
      <title>Dual degrader shows activity in acute myeloid leukemia models</title>
      <description>
        <![CDATA[Researchers in China reported the discovery and preclinical characterization of ZX-079, a novel BRD4/CBP PROTAC degrader.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729325</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729325-dual-degrader-shows-activity-in-acute-myeloid-leukemia-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/AML-cells-acute-myeloid-leukemia.webp?t=1663340307" type="image/png" medium="image" fileSize="1258935">
        <media:title type="plain">Microscopic image of acute myeloid leukemia (AML) cells.</media:title>
        <media:description type="plain">Acute myeloid leukemia cells. Credit: Cincinnati Children's
</media:description>
      </media:content>
    </item>
    <item>
      <title>Newly described selective CDK6 degrader exhibits potential in leukemia models</title>
      <description>
        <![CDATA[Researchers from Specally (Wuhan) Life Technology Co. Ltd. have disclosed the discovery and preclinical profile of WWZ-11-098, a non-palbociclib-based, selective cyclin-dependent kinase 6 (CDK6) degrader in models of leukemia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729154</guid>
      <pubDate>Tue, 03 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729154-newly-described-selective-cdk6-degrader-exhibits-potential-in-leukemia-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Leukemia.webp?t=1588713330" type="image/png" medium="image" fileSize="421137">
        <media:title type="plain">Leukemia illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>ARV-6723 shows robust efficacy in solid tumors</title>
      <description>
        <![CDATA[Mitogen-activated protein kinase kinase kinase kinase 1 (HPK1) is a serine/threonine protein kinase that is expressed in the hematopoietic compartment, exerting regulatory functions in myeloid and innate immune cells. It has been associated with decreased T-cell activation and proliferation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729135</guid>
      <pubDate>Mon, 02 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729135-arv-6723-shows-robust-efficacy-in-solid-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Targeted-cancer-cell.webp?t=1748961673" type="image/jpeg" medium="image" fileSize="966728">
        <media:title type="plain">Cancer cell in the cross-hairs</media:title>
      </media:content>
    </item>
    <item>
      <title>Triana Biomedicines patents ALK degradation inducers</title>
      <description>
        <![CDATA[Triana Biomedicines Inc. has disclosed ALK tyrosine kinase receptor degradation inducers intended for use in the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729124</guid>
      <pubDate>Fri, 27 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729124-triana-biomedicines-patents-alk-degradation-inducers</link>
    </item>
    <item>
      <title>Gan &amp; Lee Pharmaceuticals patents SMARCA2/4-degrading PROTACs</title>
      <description>
        <![CDATA[Gan & Lee Pharmaceuticals Co. Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)- and/or SMARCA4-targeting moiety.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729064</guid>
      <pubDate>Thu, 26 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729064-gan-and-lee-pharmaceuticals-patents-smarca2-4-degrading-protacs</link>
    </item>
    <item>
      <title>Hengrui Pharmaceuticals reports PROTACs targeting BCL6</title>
      <description>
        <![CDATA[Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728945</guid>
      <pubDate>Thu, 19 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728945-hengrui-pharmaceuticals-reports-protacs-targeting-bcl6</link>
    </item>
    <item>
      <title>Shenzhen Targetrx reports EGFR-targeted PROTACs</title>
      <description>
        <![CDATA[Shenzhen Targetrx Inc. has designed new proteolysis targeting chimeric (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to an EGFR L858R-, L858R/T790M double mutant- and L858R/T790M/C797S triple mutant-targeting moiety through a linker reported to useful for the treatment of non-small-cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728930</guid>
      <pubDate>Wed, 18 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728930-shenzhen-targetrx-reports-egfr-targeted-protacs</link>
    </item>
    <item>
      <title>Ascentage Pharma Group patents BTK PROTAC degraders</title>
      <description>
        <![CDATA[Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have disclosed proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked to a Bruton tyrosine kinase (BTK)-targeting moiety. They are reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728913</guid>
      <pubDate>Tue, 17 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728913-ascentage-pharma-group-patents-btk-protac-degraders</link>
    </item>
    <item>
      <title>European grant supports Beactica’s BEA-17 for glioblastoma</title>
      <description>
        <![CDATA[Beactica Therapeutics AB, together with researchers at KU Leuven, has been awarded a €2.5 million (US$3.0 million) grant by the European Innovation Council (EIC) to advance BEA-17, a precision immune therapy for glioblastoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728900</guid>
      <pubDate>Tue, 17 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728900-european-grant-supports-beacticas-bea-17-for-glioblastoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-brain-tumor-treatment-GBM.webp?t=1676390636" type="image/png" medium="image" fileSize="671414">
        <media:title type="plain">Conceptual image for brain cancer treatment</media:title>
      </media:content>
    </item>
    <item>
      <title>Adlai Nortye discloses new PROTACs for STAT protein degradation</title>
      <description>
        <![CDATA[Scientists from Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a signal transducer and activator of transcription 6 (STAT6)- or STAT3-targeting moiety.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728892</guid>
      <pubDate>Mon, 16 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728892-adlai-nortye-discloses-new-protacs-for-stat-protein-degradation</link>
    </item>
    <item>
      <title>New CDK12/13 dual degrader for TNBC</title>
      <description>
        <![CDATA[Triple-negative breast cancer (TNBC) cells depend on the transcriptional kinases CDK12 and CDK13 to maintain DNA damage response gene expression and manage replication stress. Due to their functional overlap, inhibition of a single kinase may permit compensatory activity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728815</guid>
      <pubDate>Thu, 12 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728815-new-cdk12-13-dual-degrader-for-tnbc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Breast-cancer-tumor.webp?t=1755066074" type="image/jpeg" medium="image" fileSize="171386">
        <media:title type="plain">Illustration of tumor in breast</media:title>
      </media:content>
    </item>
    <item>
      <title>Innocare’s VAV1 degrader ICP-538 cleared for clinic in China</title>
      <description>
        <![CDATA[Beijing Innocare Pharma Tech Co. Ltd. has gained IND clearance in China to conduct clinical trials of ICP-538, an orally administered molecular glue degrader targeting VAV1, which is a key protein downstream of T-cell and B-cell receptors. ICP-538 is being studied for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus and multiple sclerosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728741</guid>
      <pubDate>Mon, 09 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728741-innocares-vav1-degrader-icp-538-cleared-for-clinic-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/molecular-science-research-art-2.webp?t=1749649165" type="image/jpeg" medium="image" fileSize="145862">
        <media:title type="plain">Art concept for molecular glue degradation</media:title>
      </media:content>
    </item>
    <item>
      <title>Uppthera divulges Aurora A kinase degrading PROTACs</title>
      <description>
        <![CDATA[Uppthera Inc. has patented new proteolysis targeting chimera (PROTAC) compounds comprising cereblon E3 ubiquitin ligase-binding moiety covalently linked to Aurora kinase A (AURKA; ARK1)-targeting moiety. They are reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728464</guid>
      <pubDate>Mon, 02 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728464-uppthera-divulges-aurora-a-kinase-degrading-protacs</link>
    </item>
    <item>
      <title>Novel JAK1/2 PROTAC degrader effectively improves IBD</title>
      <description>
        <![CDATA[Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is a chronic immune-mediated inflammatory disorder with limited long-term therapeutic options. Proteolysis-targeting chimeras (PROTACs) offer a promising strategy for IBD by enabling selective degradation of disease-relevant proteins and potentially improving efficacy and safety.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728456</guid>
      <pubDate>Mon, 02 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728456-novel-jak1-2-protac-degrader-effectively-improves-ibd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-inflammatory-bowel-disease-IBD-Crohn.webp?t=1706553250" type="image/jpeg" medium="image" fileSize="247467">
        <media:title type="plain">Art concept for inflammation in the intestines</media:title>
      </media:content>
    </item>
  </channel>
</rss>
